论文部分内容阅读
目的评价长疗程聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法 45例接受聚乙二醇干扰素α-2b联合利巴韦林治疗未能达到快速应答(rapid virological response,RVR)的慢性丙型肝炎患者被随机分成两组,分别完成聚乙二醇干扰素联合利巴韦林48周治疗(普通疗程组)和72周治疗(长疗程组),在完成治疗后继续随访24周,并观察药物副反应。结果普通疗程组和长疗程组在治疗结束时病毒应答(end treatment virological response,ETVR)分别为(52.1%对77.2%,P(0.05),但是长疗程组持续病毒学应答(sustained virological response,SVR)显著高于普通疗程组(72.7%对34.7%,P<0.05)。结论长疗程聚乙二醇干扰素能够显著提高无快速应答慢性丙肝患者的SVR,副反应随疗程增加未见增加。
Objective To evaluate the clinical efficacy of long-term pegylated interferon plus ribavirin in the treatment of chronic hepatitis C Methods A total of 45 patients with chronic hepatitis C who did not achieve rapid virological response (RVR) after treatment with peginterferon alfa-2b plus ribavirin were randomized into two groups to complete the pegylated The combined treatment of ribavirin for 48 weeks (general treatment group) and 72 weeks (long course group) was followed up for 24 weeks after completion of treatment, and drug side effects were observed. Results The end of treatment (ETVR) at the end of treatment was (52.1% vs. 77.2%, P (0.05), respectively), but the sustained virological response (SVR) ) Was significantly higher than that of the general treatment group (72.7% vs 34.7%, P <0.05) .Conclusion Long course of pegylated interferon can significantly increase the SVR of patients without rapid response to chronic hepatitis C, with no increase of side effects.